Financial Report: Lilly 1Q

Lilly 1Q

1Q Revenues: $5.0 billion (+5%)

1Q Earnings: $1.3 billion (+18%)

Comments: Product sales were $4.9 billion (+4%) in the quarter. Zyprexa sales were flat at $1.1 billion; Cymbalta sales were $709.3 million (+17%); Humalog sales were up 11% to $450.6 million; Gemzar sales were $367.8 million (-14%). U.S. revenue was up 13% to $2.9 billion. Revenue outside the U.S. was down 4% to $2.2 billion, due to the impact of foreign exchange. Collaboration and other revenue was $155.2 million (+58%), primarily due to the inclusion of Erbitux revenue as a result of the ImClone acquisition. Lilly recognized $94.1 million for Erbitux, comprised of collaboration revenue of $68.0 million and product sales of $26.1 million.